Antitrust Antitrust

Alliance Healthcare continues to defend UK antitrust charges over drug deals (correct*)

By Simon Zekaria
  • 24 Mar 2021 10:55
  • 25 Mar 2021 08:13
Alliance Healthcare "continues to defend" itself against UK charges of infringing competition law in deals to acquire the antibiotic Nitrofurantoin, according to a US securities filing submitted by AmerisourceBergen, which plans to buy Alliance.

AmerisourceBergen agreed in January to acquire the majority of Alliance Healthcare from peer Walgreens Boots Alliance fo

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Simon Zekaria

Senior Correspondent

Simon Zekaria is a senior correspondent in London, covering UK regulation. Prior to joining MLex, Simon reported on business news for The Wall Street Journal, including on telecommunications, media, technology and consumer affairs. Simon was also a writer for the WSJ on diverse subjects such as Brexit, UK politics and global sport. Simon was previously a correspondent on competition issues and European politics for Thomson Reuters and Agence France-Presse in Brussels. Simon is a graduate of Edinburgh University, with Masters degrees in literature and law. A French speaker, he has studied at the Sorbonne University, Paris.

Discover MLex

Stay on top of global regulatory developments

Latest News